Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05948566 · ClinicalTrials.gov registry record · Phase 2
Strategy for Improving Stroke Treatment Response
A Phase 2 study of Ischemic Stroke, sponsored by Translational Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05948566 is a Phase 2 study of Ischemic Stroke that is actively recruiting participants, run by Translational Sciences. The registered enrollment target is 300 participants, below the 1,459-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05948566, a Phase 2 study of Ischemic Stroke, is actively recruiting participants, sponsored by Translational Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Conditions Studied
Interventions
- BIOLOGICAL TS23
Study Locations (20)
California
- UCSD Health La Jolla - La Jolla
- Kaiser Permanente Los Angeles - Los Angeles
- Sutter Medical Center - Sacramento
- UCSD Medical Center- Hillcrest Hospital - San Diego
Arizona
- Banner University Medical Center - Phoenix
- Mayo Clinic Phoenix - Phoenix
- Banner University Medical Center - Tucson - Tucson
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Florida
- UF Health Shands Hospital - Gainesville
- Jackson Memorial Hospital - Miami
Kentucky
- Baptist Healthcare System, Inc. - Lexington
- University of Louisville Hospital - Louisville
Massachusetts
- Brigham and Women's Hospital - Boston
- Massachusetts General Hospital - Boston
Alabama
- University of Alabama Hospital - Birmingham
Delaware
- Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05948566
The ClinicalTrials.gov registry entry for NCT05948566 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,459-participant average among 66 other Ischemic Stroke trials with a reported enrollment target (79% lower). The listed sponsor is Translational Sciences, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Stroke appearing as the primary indexed condition, and to 1 intervention - of which TS23 is the first listed.
NCT05948566 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05948566 about?
NCT05948566 is a clinical study titled "Strategy for Improving Stroke Treatment Response". SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
What is the current status of trial NCT05948566?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2024-03-18. Estimated completion is 2027-12.
What conditions does trial NCT05948566 study?
This clinical trial studies the following conditions: Ischemic Stroke.
What interventions are being tested in trial NCT05948566?
The interventions under investigation include: TS23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05948566?
This trial is sponsored by Translational Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05948566 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial
RECRUITING · Phase 2
-
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
RECRUITING · Phase 2
-
Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke
RECRUITING · Phase 2
-
Dietary Nitrate Supplements and Ischemic Stroke Recovery
COMPLETED · Phase 2
-
Mayo Acute Stroke Trial for Enhancing Recovery
COMPLETED · Phase 2
-
Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.